Saturday - May 17, 2025
ALBUQUERQUE, N.M., Nov. 16, 2023 /PRNewswire/ -- Ambetter from Western Sky Community Care, a product offered by a wholly owned subsidiary of Centene Corporation (NYSE: CNC) which provides insurance to under-insured and uninsured populations through the State Based Exchange (beWellnm), announced today that it will offer a variety of affordable health insurance plans to residents statewide in New Mexico for 2024. BeWellnm's open enrollment for New Mexico runs from Nov. 1, 2023, through Jan. 15, 2024.
"Health insurance is a vital resource for people in New Mexico that enables them to take charge of their health. Ambetter from Western Sky Community Care is proud to work with beWellnm and provide health plans to fit different budgets and needs throughout the State of New Mexico," said Jean Wilms, plan president and CEO of Western Sky Community Care.
Ambetter from Western Sky Community Care offers its members access to quality care, convenient services, and valuable rewards. 2024 benefits and offerings include:
Ambetter from Western Sky Community Care is offered in all counties in New Mexico. New Mexico residents interested in learning more about Ambetter from Western Sky Community Care or enrolling in a health plan during the open enrollment period may visit Ambetter.WesternSkyCommunityCare.com.
About Ambetter from Western Sky Community Care
Ambetter from Western Sky Community Care is underwritten by Western Sky Community Care, Inc., which is a Qualified Health Plan issuer in the New Mexico Health Insurance Marketplace. For more information visit https://ambetter.westernskycommunitycare.com/. For information on your right to receive an Ambetter from Western Sky Community Care plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit www.ambetterhealth.com and scroll to the bottom of the page.
Last Trade: | US$61.78 |
Daily Change: | 1.72 2.86 |
Daily Volume: | 4,143,686 |
Market Cap: | US$31.190B |
April 25, 2025 February 24, 2025 February 04, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load